Miikka Vikkula/LinkedIn
Dec 25, 2025, 13:41
Miikka Vikkula on a Treatment Advance: How Sirolimus Dosing Can Be Adapted for Vascular Malformations
Miikka Vikkula, Vice President at International Society for the Study of Vascular Anomalies (ISSVA), shared a post on LinkedIn:
“Congratulations Emmanuel on this online publication showing how sirolimus treatment can be adapted to patients’ needs. Most patients with slow-flow vascular malformations benefit to some extent, and many experience significant symptom reduction even with intermittent dosing. This is a big step forward in the multimodal management of vascular malformations”
Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Sep 1, 2026, 18:13Ramsha Batool: Chemotherapy-Induced Anemia Impacts Quality of Life in Breast Cancer
-
Sep 1, 2026, 18:09Natalya Shynhera: Using Anemia to Teach Medical English in Real Clinical Practice
-
Sep 1, 2026, 18:06Wei Du: New Therapeutic Potential for PARP Inhibitors in MLL-Rearranged Leukemia
-
Sep 1, 2026, 18:03Tobias Tichelbäcker: PRAGUE-26 Shows Catheter Lysis Beats Anticoagulation Without Ultrasound
-
Sep 1, 2026, 18:00Baptiste Thibault: My First Publication as First Author on Ionized Calcium Monitoring Before Citrate-CRRT
-
Sep 1, 2026, 17:51Nadezhda Vasilyeva: Shifting the Boundaries of Acute Ischemic Stroke Management
-
Sep 1, 2026, 17:49Malik Ghannam: Recent Venous Thrombosis Risk Factors May Help Explain Cryptogenic Stroke in Young Adults
-
Sep 1, 2026, 17:42Rishabh Jain: Renal Artery FMD Is Managed With Balloon Angioplasty Alone
-
Sep 1, 2026, 17:42Caitlin R: The Brain’s Need to Find Patterns